hederagenin profile

Hederagenin is a triterpenoid saponin found in the plant Hedera helix (common ivy). It has been studied for its potential biological activities, including anti-inflammatory, antiviral, and anticancer effects. The compound has also been shown to inhibit the growth of certain types of bacteria. Hederagenin is synthesized in plants through a series of complex enzymatic reactions involving the condensation of isopentenyl diphosphate units. Its biological activities have sparked interest in its potential therapeutic applications, leading to ongoing research to understand its mechanisms of action and develop new drugs based on its structure.'

ID Source	ID
PubMed CID	73299
CHEMBL ID	486400
CHEBI ID	69579
SCHEMBL ID	359809
MeSH ID	M0085532

Synonym
astrantiagenin e
465-99-6
hederagenol
caulosapogenin
olean-12-en-28-oic acid,23-dihydroxy-
olean-12-en-28-oic acid,23-dihydroxy-, (3.beta.,4.alpha.)-
nsc24954
hederagenin ,
nsc-24954
einecs 207-369-9
nsc 24954
hederagenic acid
(3beta,4alpha)-3,23-dihydroxyolean-12-en-28-oic acid
(3-beta,4-alpha)-3,23-dihydroxyolean-12-en-28-oic acid
olean-12-en-28-oic acid, 3,23-dihydroxy-, (3beta,4alpha)-
olean-12-en-28-oic acid, 3beta,23-dihydroxy-
olean-12-en-28-oic acid, 3,23-dihydroxy-, (3-beta,4-alpha)-
(4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-10-hydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
4-epi-hederagenin
CHEMBL486400
chebi:69579 ,
S3899
AKOS016036289
rqf57j8212 ,
olean-12-en-28-oic acid, 3-beta,23-dihydroxy-
unii-rqf57j8212
hederagenine
(3beta)-3,23-dihydroxyolean-12-en-28-oic acid
hederagenin, (+)-
olean-12-en-28-oic acid, 3,23-dihydroxy-, (3.beta.,4.alpha.)-
olean-12-en-28-oic acid, 3.beta.,23-dihydroxy-
hederagenin [mi]
bdbm50442880
H1645
SCHEMBL359809
Q-100493
mfcd00017385
HY-N0256
CS-5454
AS-68383
(4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-10-hydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylicacid
hederagenin, >=97% (hplc)
Q5697238
(4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid
hederagenin,(s)
3beta,4alpha-3,23-dihydroxyolean-12-en-28-oic acid
CCG-269472
olean-12-en-28-oic acid, 3,23-dihydroxy-, (3b,4a)-
3ss,4a-3,23-dihydroxyolean-12-en-28-oicacid
A872247
DTXSID301029412
olean-12-en-28-oic acid, 3-beta,23-dihydroxy-(6ci,7ci,8ci)

Excerpt	Reference	Relevance
"Hederagenin is a triterpenoid saponin from some Chinese herbs with anti-inflammatory and anti-diabetic activities."	( Hederagenin inhibits high glucose-induced fibrosis in human renal cells by suppression of NLRP3 inflammasome activation through reducing cathepsin B expression. Jiang, H; Ma, W; Yang, G; Yang, W; Yi, Q, 2023)	3.07
"Hederagenin is a pentacyclic triterpenoid that is widely distributed as the main pharmaceutical ingredient in various medicinal plants. "	( Advances in the anti-tumor potential of hederagenin and its analogs. Bi, Y; Fang, X; Han, S; Li, H; Lu, X; Xie, W; Yang, D, 2023)	2.62
"Hederagenin (Hed) is a pentacyclic triterpenoid saponin extracted from various natural medicinal plants and exhibits numerous biological activities and may offer benefits against bone-related conditions."	( Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption. Ding, J; Li, Y; Liang, J; Lin, X; Liu, Q; Song, F; Su, Y; Tian, K; Wang, D; Wang, Z; Xu, J; Zhan, Y; Zhao, J, 2020)	2.72
"Hederagenin (HDG) is a pentacyclic triterpenoid saponin widely distributed in various plants."	( The protective effect of Hederagenin on pulmonary fibrosis by regulating the Ras/JNK/NFAT4 axis in rats. Deng, L; He, Y; Huang, Q; Ma, W; Xiong, G, 2020)	1.58
"Hederagenin is a representative precursor for hemolytic saponin in plants."	( Transcriptomic Analysis of Kalopanax septemlobus and Characterization of KsBAS, CYP716A94 and CYP72A397 Genes Involved in Hederagenin Saponin Biosynthesis. Choi, YE; Chun, JH; Han, JY; Hwang, HS; Lee, H; Oh, SA; Park, SB, 2018)	1.41
"Hederagenin is an effective constituent of many medical plants, such as Clematidis Radix, and has a wide range of applications in anti-tumor, anti-inflammatory, antidepressant, hepatoprotective antibacterial, et al. "	( [Biosynthesis analysis of hederagenin pathway and its construction in yeast cells]. Dai, ZB; Li, WX; Lu, FP; Ma, XL; Wang, D; Zhang, XL, 2018)	2.22
"Hederagenin was found to be an essential moiety for the exhibition of antimutagenicity."	( Essential moiety for antimutagenic and cytotoxic activity of hederagenin monodesmosides and bisdesmosides isolated from the stem bark of Kalopanax pictus. Jung, GO; Kim, DW; Lee, KT; Park, HJ; Park, KY; Sohn, IC, 2000)	1.27

Excerpt	Reference	Relevance
"Hederagenin (HE) plays a protective role by inhibiting cell proliferation and ameliorating fibrosis. "	( The protective effect of hederagenin on renal fibrosis by targeting muscarinic acetylcholine receptor. He, L; Yang, W, 2022)	2.47

Excerpt	Reference	Relevance
"Treatment with hederagenin (10, 30 and 100μM) resulted in inhibited levels of protein expression of lipopolysaccharide-stimulated iNOS, COX-2, and NF-κB as well as production of NO, PGE2, TNF-α, IL-1β, and IL-6 induced by lipopolysaccharide."	( Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice. An, WG; Cho, IJ; Chun, W; Jegal, KH; Ju, SA; Jung, JY; Kim, SC; Kim, SH; Kim, YW; Ku, SK; Lee, C; Lee, CW; Park, SM; Son, Y; Zhao, R, 2015)	2.2

Excerpt	Reference	Relevance
" Consequently, the validated method could be successfully and precisely applied to the pharmacokinetic study of asperosaponin VI and its metabolites."	( Pharmacokinetics study of asperosaponin VI and its metabolites cauloside A, HN saponin F and hederagenin. Chang, YX; Gao, XM; Han, LF; Huo, Y; Liu, EW; Wang, JL; Wang, L; Wang, T, 2014)	0.62

Excerpt	Reference	Relevance
" The bioavailability of 29 was significantly improved in comparison with its aglycon."	( Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid. Chen, C; Cheng, K; Dai, L; Hu, K; Li, H; Liu, L; Sun, H; Wen, X; Xu, Q; Yuan, H, 2021)	0.62

Excerpt	Relevance	Reference
" The four diterpene acids dosed at 25 approximately 100 mg/kg had dose-dependently anti-asthmatic effects: 7-oxo-sandaracopimaric acid > 17-hydroxy-ent-kaur-15-en-19-oic acid > kaurenoic acid > hederagenin."	( Inhibitory effects of diterpene acids from root of Aralia cordata on IgE-mediated asthma in guinea pigs. Cho, JH; Kim, CJ; Lee, JY; Sim, SS; Whang, WK, 2010)	0.55

Role	Description
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pentacyclic triterpenoid
dihydroxy monocarboxylic acid	Any hydroxy monocarboxylic acid carrying at least two hydroxy groups.
sapogenin	Any organic polycyclic compound that is the aglycon moiety of a saponin; sapogenins may be steroids or triterpenoids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	IC50 (µMol)	40.0000	0.0320	1.4649	4.8000	AID1617776
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	20.0000	0.0000	0.5369	10.0000	AID1617466; AID1617467; AID1617468
Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)	IC50 (µMol)	40.0000	0.0001	1.6847	9.3200	AID1617774
Tissue factor	Homo sapiens (human)	IC50 (µMol)	0.0002	0.0001	0.7344	10.0000	AID1436859
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	IC50 (µMol)	0.8913	0.1047	2.7195	7.0795	AID977603
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Ki	0.6800	0.0800	2.4688	9.8000	AID977604
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	IC50 (µMol)	3.8019	0.0500	2.3797	9.7000	AID977600
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	Ki	2.1100	0.0440	1.3630	5.0000	AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cell surface receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
MAPK cascade	Epidermal growth factor receptor	Homo sapiens (human)
ossification	Epidermal growth factor receptor	Homo sapiens (human)
embryonic placenta development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
hair follicle development	Epidermal growth factor receptor	Homo sapiens (human)
translation	Epidermal growth factor receptor	Homo sapiens (human)
signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
activation of phospholipase C activity	Epidermal growth factor receptor	Homo sapiens (human)
salivary gland morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
midgut development	Epidermal growth factor receptor	Homo sapiens (human)
learning or memory	Epidermal growth factor receptor	Homo sapiens (human)
circadian rhythm	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
diterpenoid metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
cerebral cortex cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell growth	Epidermal growth factor receptor	Homo sapiens (human)
lung development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of superoxide anion generation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
response to cobalamin	Epidermal growth factor receptor	Homo sapiens (human)
response to hydroxyisoflavone	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to reactive oxygen species	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of protein catabolic process	Epidermal growth factor receptor	Homo sapiens (human)
vasodilation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ovulation cycle	Epidermal growth factor receptor	Homo sapiens (human)
hydrogen peroxide metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
tongue development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA repair	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA replication	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of bone resorption	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Epidermal growth factor receptor	Homo sapiens (human)
regulation of JNK cascade	Epidermal growth factor receptor	Homo sapiens (human)
symbiont entry into host cell	Epidermal growth factor receptor	Homo sapiens (human)
protein autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
astrocyte activation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Epidermal growth factor receptor	Homo sapiens (human)
digestive tract morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
neuron projection morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
protein insertion into membrane	Epidermal growth factor receptor	Homo sapiens (human)
response to calcium ion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of glial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Epidermal growth factor receptor	Homo sapiens (human)
eyelid development in camera-type eye	Epidermal growth factor receptor	Homo sapiens (human)
response to UV-A	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of mucus secretion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to amino acid stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to cadmium ion	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to xenobiotic stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
liver regeneration	Epidermal growth factor receptor	Homo sapiens (human)
cell-cell adhesion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein kinase C activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of prolactin secretion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of cardiocyte differentiation	Epidermal growth factor receptor	Homo sapiens (human)
neurogenesis	Epidermal growth factor receptor	Homo sapiens (human)
multicellular organism development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of endothelial cell proliferation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukocyte chemotaxis involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukocyte migration involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene production involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene metabolic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
humoral immune response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of angiogenesis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
positive regulation of bone mineralization	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
dendritic cell migration	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
glucose homeostasis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of fat cell differentiation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of insulin secretion	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of vascular wound healing	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of wound healing	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of inflammatory response to wounding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of cytokine production involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of cellular response to oxidative stress	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene A4 biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of response to endoplasmic reticulum stress	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of sprouting angiogenesis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cell	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipoxin biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
positive regulation of gene expression	Tissue factor	Homo sapiens (human)
positive regulation of interleukin-8 production	Tissue factor	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Tissue factor	Homo sapiens (human)
activation of plasma proteins involved in acute inflammatory response	Tissue factor	Homo sapiens (human)
activation of blood coagulation via clotting cascade	Tissue factor	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tissue factor	Homo sapiens (human)
blood coagulation	Tissue factor	Homo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathway	Tissue factor	Homo sapiens (human)
protein processing	Tissue factor	Homo sapiens (human)
positive regulation of cell migration	Tissue factor	Homo sapiens (human)
positive regulation of TOR signaling	Tissue factor	Homo sapiens (human)
positive regulation of angiogenesis	Tissue factor	Homo sapiens (human)
positive regulation of positive chemotaxis	Tissue factor	Homo sapiens (human)
cytokine-mediated signaling pathway	Tissue factor	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
arachidonate 5-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
hydrolase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
serine-type endopeptidase activity	Tissue factor	Homo sapiens (human)
protease binding	Tissue factor	Homo sapiens (human)
protein binding	Tissue factor	Homo sapiens (human)
phospholipid binding	Tissue factor	Homo sapiens (human)
cytokine receptor activity	Tissue factor	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular region	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
extracellular space	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nucleoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear matrix	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear membrane	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
secretory granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
perinuclear region of cytoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
ficolin-1-rich granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
extracellular space	Tissue factor	Homo sapiens (human)
plasma membrane	Tissue factor	Homo sapiens (human)
external side of plasma membrane	Tissue factor	Homo sapiens (human)
cell surface	Tissue factor	Homo sapiens (human)
membrane	Tissue factor	Homo sapiens (human)
collagen-containing extracellular matrix	Tissue factor	Homo sapiens (human)
serine-type peptidase complex	Tissue factor	Homo sapiens (human)
plasma membrane	Tissue factor	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (124)

Assay ID	Title	Year	Journal	Article
AID977604	Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1617461	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1292212	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel hederagenin-triazolyl derivatives as potential anti-cancer agents.
AID1503260	Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID977600	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1617775	Inhibition of human recombinant 5-LOX expressed in insect cells assessed residual activity using arachidonic acid at 42 uM as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol o	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1503262	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1335272	Cytotoxicity against dog DH82 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID1256523	Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Hederagenin as a triterpene template for the development of new antitumor compounds.
AID1903284	Cytotoxicity against human KBV cells assessed as decrease in cell survival rate at 10 uM measured after 72 hrs in presence of paclitaxel by MTT assay	2022	European journal of medicinal chemistry, Mar-15, Volume: 232	Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles.
AID623339	Induction of apoptosis in human M14 cells assessed as activation of caspase-3 at 50 uM after 8 to 24 hrs by Western blot analysis	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Triterpenoid constituents from the roots of Paeonia rockii ssp. rockii.
AID1503734	Antiproliferative activity against human KB cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1543904	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID1292209	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel hederagenin-triazolyl derivatives as potential anti-cancer agents.
AID393219	Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Haemolytic activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural lupane- and oleanane-type saponins.
AID1442271	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.
AID1617774	Inhibition of human recombinant 5-LOX expressed in insect cells assessed as decrease in production of 5-HPETE and 5-HETE using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric io	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1617462	Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1493998	Cytotoxicity against human KBVIN cells after 72 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.
AID1442275	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.
AID1503748	Cell cycle arrest in human MKN45 cells assessed as accumulation at G2/M-phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 19%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1503267	Antileishmanial activity against Leishmania infantum MHOM/BR/70/BH46 intracellular amastigotes infected in canine DH82 cells assessed as as inhibition of cell growth at 1000 uM incubated for 48 hrs by ELISA method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1335274	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID623342	Induction of apoptosis in human M14 cells assessed as increase in hypodiploid cells up to 25 uM after 24 hrs using propidium iodide staining by flow cytometry	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Triterpenoid constituents from the roots of Paeonia rockii ssp. rockii.
AID1503746	Cell cycle arrest in human MKN45 cells assessed as accumulation at G1-phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 67%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1503743	Cell cycle arrest in human MKN45 cells assessed as accumulation at S-phase at 10 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 15%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1503737	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID393220	Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Haemolytic activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural lupane- and oleanane-type saponins.
AID1503275	Cytotoxicity in African green monkey BGM cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1503268	Antileishmanial activity against Leishmania infantum MHOM/BR/70/BH46 intracellular amastigotes infected in canine DH82 cells assessed as as inhibition of cell growth incubated for 48 hrs by ELISA method	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1494000	Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.
AID393223	Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Haemolytic activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural lupane- and oleanane-type saponins.
AID1256525	Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Hederagenin as a triterpene template for the development of new antitumor compounds.
AID772918	Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20	Bioactive oleanane-type saponins from the rhizomes of Anemone taipaiensis.
AID1503739	Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID772915	Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20	Bioactive oleanane-type saponins from the rhizomes of Anemone taipaiensis.
AID627012	Inhibition of NF-kappaB-induced iNOS mRNA expression in TNF-alpha-stimulated human HepG2 cells at 0.1 to 10 uM after 1 hr by RT-PCR analysis	2011	Journal of natural products, Sep-23, Volume: 74, Issue:9	Anti-inflammatory triterpenoid saponins from the stem bark of Kalopanax pictus.
AID1503270	Selectivity index, ratio of CC50 for dog DH82 cells to IC50 for antileishmanial activity against Leishmania infantum MHOM/BR/70/BH46 intracellular amastigotes infected in canine DH82 cells	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1503742	Cell cycle arrest in human MKN45 cells assessed as accumulation at G1-phase at 10 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 67%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1292214	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel hederagenin-triazolyl derivatives as potential anti-cancer agents.
AID1617467	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1503745	Cell cycle arrest in human MKN45 cells assessed as apoptotic cell accumulation at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 1.51%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1256528	Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Hederagenin as a triterpene template for the development of new antitumor compounds.
AID1503278	Selectivity index, ratio of CC50 for human HepG2 cells to IC50 for antileishmanial activity against Leishmania infantum MHOM/BR/70/BH46 intracellular amastigotes infected in canine DH82 cells	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1335269	Selectivity index, ratio of LD50 for dog DH82 cells to IC50 for Leishmania infantum MHOM/BR/70/BH46 promastigotes infected in dog DH82 cells	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID1543901	Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID1436859	Inhibition of LPS-induced tissue factor procoagulant activity in human THP1 cells preincubated for 1 hr followed by LPS addition measured after 5 hrs using factor 10a chromogenic substrate in presence of prothrombin complex	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Microbial hydroxylation and glycosylation of pentacyclic triterpenes as inhibitors on tissue factor procoagulant activity.
AID1442277	Cytotoxicity against human KBVIN cells assessed as reduction in cell viability after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID623340	Induction of apoptosis in human M14 cells assessed as activation of caspase-3 at 50 uM after 24 hrs by Western blot analysis presence of polycaspase inhibitor z-VAD-fmk	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Triterpenoid constituents from the roots of Paeonia rockii ssp. rockii.
AID1530706	Reversal of P-gp-mediated drug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring cell survival at 5 uM after 72 hrs by MTT assay (Rvb = 98 +/- 19%)	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthesis and biological evaluation of novel H6 analogues as drug resistance reversal agents.
AID623338	Cytotoxicity against human M14 cells after 48 hrs by MTT assay	2011	Journal of natural products, Oct-28, Volume: 74, Issue:10	Triterpenoid constituents from the roots of Paeonia rockii ssp. rockii.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1617779	Inhibition of ovine recombinant COX1 assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1335273	Selectivity index, ratio of LD50 for African green monkey BGM cells to IC50 for Leishmania infantum MHOM/BR/70/BH46 promastigotes infected in dog DH82 cells	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID1503738	Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1543906	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID1617460	Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1503263	Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1543905	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID1543903	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID1617464	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1503744	Cell cycle arrest in human MKN45 cells assessed as accumulation at G2/M-phase at 10 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 19%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1503264	Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID393222	Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Haemolytic activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural lupane- and oleanane-type saponins.
AID403015	Induction of quinone reductase	2005	Journal of natural products, Jul, Volume: 68, Issue:7	Limnophilaspiroketone, a highly oxygenated phenolic derivative from Limnophila geoffrayi.
AID1617780	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1493994	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.
AID1503740	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1617469	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1617466	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1617470	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID393224	Cell membrane permeabilization in human WS1 cells assessed as drug level causing decrease in calcein fluorescence	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Haemolytic activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural lupane- and oleanane-type saponins.
AID977601	Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1617781	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis r	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID402639	Cytotoxicity against human BC cells by colorimetric method	2005	Journal of natural products, Jul, Volume: 68, Issue:7	Bioactive constituents of the leaves of Phyllanthus polyphyllus var. siamensis.
AID1494001	Hemolytic activity against New Zealand rabbit erythrocytes measured after 60 mins	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.
AID402638	Cytotoxicity against human KB cells by colorimetric method	2005	Journal of natural products, Jul, Volume: 68, Issue:7	Bioactive constituents of the leaves of Phyllanthus polyphyllus var. siamensis.
AID1335275	Cytotoxicity against African green monkey BGM cells assessed as decrease in cell viability after 48 hrs by MTT assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID1493996	Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.
AID772917	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20	Bioactive oleanane-type saponins from the rhizomes of Anemone taipaiensis.
AID1503736	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1503730	Antiproliferative activity against human MKN45 cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1442278	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.
AID1503269	Cytotoxicity in dog DH82 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1617777	Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1335271	Antiparasitic activity against Leishmania infantum MHOM/BR/70/BH46 promastigotes infected in dog DH82 cells after 48 hrs by ELISA method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID1617776	Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol orange as	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1761200	Reversal of P-glycoprotein mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring cell survival rate at 10 uM measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and biological evaluation of hederagenin derivatives with improved aqueous solubility and tumor resistance reversal activity.
AID1442276	Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.
AID626970	Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay	2011	Journal of natural products, Sep-23, Volume: 74, Issue:9	Anti-inflammatory triterpenoid saponins from the stem bark of Kalopanax pictus.
AID1335270	Antiparasitic activity against Leishmania infantum MHOM/BR/70/BH46 promastigotes infected in dog DH82 cells at 1000 uM after 48 hrs by ELISA method	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID393218	Toxicity in sheep erythrocytes assessed as induction of hemolysis	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Haemolytic activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural lupane- and oleanane-type saponins.
AID1503747	Cell cycle arrest in human MKN45 cells assessed as accumulation at S-phase at 10 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 15%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1503741	Cell cycle arrest in human MKN45 cells assessed as apoptotic cell accumulation at 10 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 1.51%)	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1442274	Hemolytic activity against New Zealand rabbit erythrocytes after 60 mins	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.
AID1256526	Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Hederagenin as a triterpene template for the development of new antitumor compounds.
AID627013	Inhibition of NF-kappaB-induced COX2 mRNA expression in TNF-alpha-stimulated human HepG2 cells at 0.1 to 10 uM after 1 hr by RT-PCR analysis	2011	Journal of natural products, Sep-23, Volume: 74, Issue:9	Anti-inflammatory triterpenoid saponins from the stem bark of Kalopanax pictus.
AID977603	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1503261	Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID772916	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20	Bioactive oleanane-type saponins from the rhizomes of Anemone taipaiensis.
AID1617468	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1335276	Selectivity index, ratio of LD50 for human HepG2 cells to IC50 for Leishmania infantum MHOM/BR/70/BH46 promastigotes infected in dog DH82 cells	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
AID1256527	Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Hederagenin as a triterpene template for the development of new antitumor compounds.
AID1728066	Activation of AMPK in human Huh-7 cells assessed as increase in AMPK phosphorylation at Thr172 residue at 10 uM measured after 12 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Synthesis and anti-inflammatory activity of saponin derivatives of δ-oleanolic acid.
AID1493992	Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay	2018	Journal of natural products, 03-23, Volume: 81, Issue:3	Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.
AID1503253	Antiparasitic activity against Leishmania infantum	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1503277	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID1503735	Antiproliferative activity against human KBV cells after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1292208	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel hederagenin-triazolyl derivatives as potential anti-cancer agents.
AID772914	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20	Bioactive oleanane-type saponins from the rhizomes of Anemone taipaiensis.
AID1292211	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel hederagenin-triazolyl derivatives as potential anti-cancer agents.
AID1617778	Inhibition of ovine recombinant COX1 assessed as decrease in formation of PGE2 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID750462	Antiviral activity against pseudo HCV infected in human 293T cells assessed as inhibition of HCV pseudo particles entry at 10 uM after 72 hrs by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Development of oleanane-type triterpenes as a new class of HCV entry inhibitors.
AID1503276	Selectivity index, ratio of CC50 for African green monkey BGM cells to IC50 for antileishmanial activity against Leishmania infantum MHOM/BR/70/BH46 intracellular amastigotes infected in canine DH82 cells	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Leishmanicidal and cytotoxic activity of hederagenin-bistriazolyl derivatives.
AID393221	Cytotoxicity against human WS1 cells after 48 hrs by resazurin reduction test	2009	Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5	Haemolytic activity, cytotoxicity and membrane cell permeabilization of semi-synthetic and natural lupane- and oleanane-type saponins.
AID1503732	Antiproliferative activity against human KB cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Design, synthesis and biological evaluation of novel α-hederagenin derivatives with anticancer activity.
AID1256524	Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay	2015	European journal of medicinal chemistry, Nov-13, Volume: 105	Hederagenin as a triterpene template for the development of new antitumor compounds.
AID1292210	Cytotoxicity against human A549 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel hederagenin-triazolyl derivatives as potential anti-cancer agents.
AID402640	Cytotoxicity against human NCI-H187 cells by colorimetric method	2005	Journal of natural products, Jul, Volume: 68, Issue:7	Bioactive constituents of the leaves of Phyllanthus polyphyllus var. siamensis.
AID1543902	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay	2019	European journal of medicinal chemistry, Apr-15, Volume: 168	Hederagenin amide derivatives as potential antiproliferative agents.
AID1617463	Antiproliferative activity against human KB-VIN10 cells incubated for 72 hrs by SRB assay	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1292213	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Novel hederagenin-triazolyl derivatives as potential anti-cancer agents.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (3.13)	18.7374
1990's	8 (6.25)	18.2507
2000's	22 (17.19)	29.6817
2010's	67 (52.34)	24.3611
2020's	27 (21.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	4 (3.05%)	6.00%
Case Studies	1 (0.76%)	4.05%
Observational	1 (0.76%)	0.25%
Other	125 (95.42%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
benzoic acid Benzoic Acid: A fungistatic compound that is widely used as a food preservative. It is conjugated to GLYCINE in the liver and excreted as hippuric acid.. benzoic acid : A compound comprising a benzene ring core carrying a carboxylic acid substituent.. aromatic carboxylic acid : Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring.	2.06	1	benzoic acids	algal metabolite; antimicrobial food preservative; drug allergen; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor; human xenobiotic metabolite; plant metabolite
1-butanol 1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.	2.02	1	alkyl alcohol; primary alcohol; short-chain primary fatty alcohol	human metabolite; mouse metabolite; protic solvent
histamine [no description available]	2.05	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.44	2	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
croton oil [no description available]	2	1	N-acyl-hexosamine
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	2.15	1	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
albendazole [no description available]	2.21	1	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.98	3	aromatic ether; nitrile; polyether; tertiary amino compound
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.02	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
fenbendazole Fenbendazole: Antinematodal benzimidazole used in veterinary medicine.. fenbendazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted at positons 2 and 5 by (methoxycarbonyl)amino and phenylsulfanediyl groups, respectively. A broad-spectrum anthelmintic, it is used, particularly in veterinary medicine, for the treatment of nematodal infections.	2.21	1	aryl sulfide; benzimidazoles; carbamate ester	antinematodal drug
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.31	1	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.21	1	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	2.06	1
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	2.41	1	pilocarpine	antiglaucoma drug
vincristine [no description available]	2.31	1	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
uridine diphosphate Uridine Diphosphate: A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety.	2.07	1	pyrimidine ribonucleoside 5'-diphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
trichloroacetic acid Trichloroacetic Acid: A strong acid used as a protein precipitant in clinical chemistry and also as a caustic for removing warts.. trichloroacetic acid : A monocarboxylic acid that is acetic acid in which all three methyl hydrogens are substituted by chlorine.	2.02	1	monocarboxylic acid; organochlorine compound	carcinogenic agent; metabolite; mouse metabolite
azulene [no description available]	2.6	1	azulenes; mancude carbobicyclic parent; ortho-fused bicyclic arene	plant metabolite; volatile oil component
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.17	1	diazine; pyrazines	Daphnia magna metabolite
glycyrrhetinic acid [no description available]	2.86	3	cyclic terpene ketone; hydroxy monocarboxylic acid; pentacyclic triterpenoid	immunomodulator; plant metabolite
oleanolic acid [no description available]	8.07	114	hydroxy monocarboxylic acid; pentacyclic triterpenoid	plant metabolite
paeonol paeonol: structure	2.06	1	methoxybenzenes; phenols	metabolite
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.17	1	cyclic ketone; erythromycin
glycyrrhizic acid glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.	2.31	1	enone; glucosiduronic acid; pentacyclic triterpenoid; tricarboxylic acid; triterpenoid saponin	EC 3.4.21.5 (thrombin) inhibitor; plant metabolite
benorilate benorilate: was heading 1980-94 (see under SALICYLATES 1980-90); was BENORYLATE see under SALICYLATES 1975-79; BENORYLATE was see BENORILATE 1980-94; use SALICYLATES to search BENORILATE 1980-90 & BENORYLATE 1975-79; an ester of aspirin and paracetamol with analgesic, antipyretic, and anti-inflammatory activity used in the treatment of rheumatoid diseases; it has less severe side effects than aspirin	2.31	1	carbonyl compound
chromium Chromium: A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.. chromium ion : An chromium atom having a net electric charge.. chromium atom : A chromium group element atom that has atomic number 24.	2.03	1	chromium group element atom; metal allergen	micronutrient
levamisole Levamisole: An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6). levamisole : A 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole that has S configuration. It is used (generally as the monohydrochloride salt) to treat parasitic worm infections in pigs, sheep and cattle and was formerly used in humans as an adjuvant to chemotherapy for the treatment of various cancers. It is also widely used as an adulterant to coccaine.	2.17	1	6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole	antinematodal drug; antirheumatic drug; EC 3.1.3.1 (alkaline phosphatase) inhibitor; immunological adjuvant; immunomodulator
clonixin Clonixin: Anti-inflammatory analgesic.. clonixin : A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a (2-methyl-3-chlorophenyl)amino group. Used (as its lysine salt) for treatment of renal colic, muscular pain and moderately severe migraine attacks.	2.17	1	aminopyridine; organochlorine compound; pyridinemonocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; lipoxygenase inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; vasodilator agent
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	8.6	7	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
flunixin meglumine flunixin meglumine : An organoammonium salt obtained by combining flunixin with one molar equivalent of 1-deoxy-1-(methylamino)-D-glucitol. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties; used in veterinary medicine for treatment of horses, cattle and pigs.	2.17	1	organoammonium salt	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
staurosporine [no description available]	2.21	1	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	2.41	1	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
zileuton [no description available]	2.21	1	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
trichloroacetamide [no description available]	2.02	1
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	3.19	5	D-glucopyranose	epitope; mouse metabolite
ursolic acid [no description available]	2.86	3	hydroxy monocarboxylic acid; pentacyclic triterpenoid	geroprotector; plant metabolite
betulinic acid [no description available]	3.98	12	hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-HIV agent; anti-inflammatory agent; antimalarial; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; plant metabolite
medicagenic acid medicagenic acid: aglycone constituent of lucerne saponins, upon which their fungastatic & hemolytic activity depends	4.43	6	triterpenoid
secoisolariciresinol secoisolariciresinol: RN given refers to ((R-(R,R))-isomer); RN for cpd without isomeric designation not available 8/89; precursor of lignans found in human urine; structure given in first source. secoisolariciresinol : A lignan that is butane-1,4-diol in which the 2 and 3 positions are substituted by 4-hydroxy-3-methoxybenzyl groups. (-)-secoisolariciresinol : An enantiomer of secoisolariciresinol having (-)-(2R,3R)-configuration.	2.02	1	secoisolariciresinol	antidepressant; phytoestrogen; plant metabolite
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.54	2	1,2,3-triazole
betulin betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.	2.05	1	diol; pentacyclic triterpenoid	analgesic; anti-inflammatory agent; antineoplastic agent; antiviral agent; metabolite
beta-amyrin beta-amyrin: alpha-amyrin is also available; a 5 ring triterpene derived from oleanane that differs from alpha-amyrin in having the 29-carbon at the 20 position; RN given refers to (3 beta)-isomer. beta-amyrin : A pentacyclic triterpenoid that is oleanane substituted at the 3beta-position by a hydroxy group and containing a double bond between positions 12 and 13. It is one of the most commonly occurring triterpenoids in higher plants.	2.55	2	pentacyclic triterpenoid; secondary alcohol	Aspergillus metabolite; plant metabolite
alpha-amyrin alpha-amyrin: beta-amyrin is also available; a 5 ring triterpene derived from taraxasterol that differs from beta-amyrin in having the 29-carbon at the 19 position. alpha-amyrin : A pentacyclic triterpenoid that is ursane which contains a double bond between positions 12 and 13 and in which the hydrogen at the 3beta position is substituted by a hydroxy group.	2.21	1	pentacyclic triterpenoid; secondary alcohol
pulsatilla saponin a Pulsatilla saponin A: has antineoplastic activity; isolated from Pulsatilla chinensis; structure in first source. kalopanaxsaponin A : A triterpenoid saponin that is hederagenin attached to a 2-O-(6-deoxy-alpha-L-mannopyranosyl)-alpha-L-arabinopyranosyl residue at position 3 via a glycosidic linkage. It has been isolated from the stem bark of Kalopanax pictus.	2.76	3	disaccharide derivative; hydroxy monocarboxylic acid; pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; plant metabolite
echinocystic acid [no description available]	2.15	1	triterpenoid
madecassic acid [no description available]	2.31	1	monocarboxylic acid; pentacyclic triterpenoid; tetrol	antioxidant; plant metabolite
arjunolic acid arjunolic acid: oleanane type; isol from Cochlospermum tinctorium (Bixaceae); structure given in first source; RN given refers to (2alpha,3beta,4alpha)-isomer; RN for cpd without isomeric designation not avail 12/89. arjunolic acid : A pentacyclic triterpenoid that is olean-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 23 (the 2alpha,3beta stereoisomer). Isolated from Symplocos lancifolia and Juglans sinensis, it exhibits antioxidant and antimicrobial activities.	2.53	2	hydroxy monocarboxylic acid; pentacyclic triterpenoid	antibacterial agent; antifungal agent; antioxidant; metabolite
maslinic acid (2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria	3.03	4	dihydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; antineoplastic agent; antioxidant; plant metabolite
coenzyme a [no description available]	2.6	1	adenosine 3',5'-bisphosphate	coenzyme; Escherichia coli metabolite; mouse metabolite
nimustine nimustine hydrochloride : A hydrochloride obtained by combining nimustine with one equivalent of hydrochloric acid. An antineoplastic agent especially effective against malignant brain tumors.	2.08	1	hydrochloride	antineoplastic agent
uvaol uvaol: from Vauquelinia corymbosa (Rosaceae)	2.21	1	triterpenoid	metabolite
gypsogenin gypsogenin: originally from Gypsophila species; structure in first source. gypsogenin : A sapogenin that is olean-12-en-28-oic acid substituted by a beta-hydroxy group at position 3 and an oxo group at position 23.	2.53	2	aldehyde; monocarboxylic acid; pentacyclic triterpenoid; sapogenin
gardenin b gardenin B: has antineoplastic activity; structure in first source. gardenin B : A tetramethoxyflavone that is tangeretin in which the methoxy group at position 5 has been replaced by a hydroxy group.	2.02	1	monohydroxyflavone; tetramethoxyflavone	plant metabolite
syringaresinol [no description available]	2.11	1	aromatic ether; furofuran; lignan; polyether; polyphenol	plant metabolite
erythrodiol [no description available]	2.21	1	diol; pentacyclic triterpenoid; primary alcohol; secondary alcohol	plant metabolite
quillaic acid quillaic acid : A pentacyclic triterpenoid that is olean-12-ene substituted by hydroxy groups at positions 3 and 16, an oxo group at position 23 and a carboxy group at position 28 (the 3beta,16alpha stereoisomer).	2.08	1	aldehyde; hydroxy monocarboxylic acid; pentacyclic triterpenoid	anti-inflammatory agent; metabolite
soyasapogenol b soyasapogenol B: RN given for (3beta,4beta,22beta)-isomer; structure in first source. soyasapogenol B : A pentacyclic triterpenoid that is oleanane containing a double bond between positions 12 and 13 and substituted by hydroxy groups at the 3beta, 22beta and 24-positions.	2.78	3	pentacyclic triterpenoid
brassinolide brassinolide: plant growth promoting steroidal lactone from rape pollen; RN given refers to (2alpha,3alpha,5alpha,22R,23R,24S)-isomer; structure in first source	2.17	1	22-hydroxy steroid; 23-hydroxy steroid; 2alpha-hydroxy steroid; 3alpha-hydroxy steroid; brassinosteroid	plant growth stimulator; plant hormone
asiatic acid [no description available]	2.66	2	monocarboxylic acid; pentacyclic triterpenoid; triol	angiogenesis modulating agent; metabolite
gefitinib [no description available]	2.21	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
tariquidar [no description available]	2.98	3	benzamides
oleanolic acid 3-acetate oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer	2.8	3
zosuquidar trihydrochloride [no description available]	2.21	1
menisdaurilide menisdaurilide: from Ouratea reticulata structure in first source	2.02	1	benzofurans
nevadensin nevadensin: from Lysionotus pauceflora Maxim; RN & N1 from 9th CI. nevadensin : A trimethoxyflavone that is flavone substituted by methoxy groups at positions 6, 8 and 4' and hydroxy groups at positions 5 and 7 respectively.	2.02	1	dihydroxyflavone; trimethoxyflavone	plant metabolite
boswellic acid boswellic acid: ursane type; RN given refers to (3alpha,4beta)-isomer; active principle of salai guggal; see also record for salai guggal	2.21	1	triterpenoid
cussonoside b cussonoside B: triterpene saponin from Cussonia barteri bark; structure given in first source	2.08	1
17-hydroxy-ent-kaur-15-en-19-oic acid 17-hydroxy-ent-kaur-15-en-19-oic acid: diterpene constituent of Aralia cordat Thunb roots; structure	2.05	1	kaurane diterpenoid
oleanolic acid 3-o-monoglucuronide oleanolic acid 3-O-monoglucuronide: structure given in first source	2.31	1	beta-D-glucosiduronic acid
scoparianoside b scoparianoside B: isolated from the fruit of Japanese Kochia scoparia; structure given in first source	2.31	1	triterpenoid saponin
dihydrocubebin dihydrocubebin: extract of leaves of Piper guineense Schum. & Thonn.; structure. dihydrocubebin : A glycol that is butane-1,4-diol substituted at the 2- and 3-positions by (1,3-benzodioxol-5-yl)methyl groups (the R,R-configuration).	2.02	1	benzodioxoles; butanediols; glycol; lignan
pomolic acid pomolic acid: from Rosa woodsii & Hyptis capitata; structure in first source	2.07	1	triterpenoid	metabolite
arabinose [no description available]	2.03	1	L-arabinose	Escherichia coli metabolite; mouse metabolite
mevalonic acid Mevalonic Acid: A dihydroxy monocarboxylic acid and precursor in the biosynthetic pathway known as the mevalonate pathway, which produces terpenes and steroids that are vital for diverse cellular functions.. mevalonic acid : A racemate composed of equimolar amounts of (R)- and (S)-mevalonic acid.. (R)-mevalonic acid : The (R)-enantiomer of mevalonic acid.	2.17	1	3,5-dihydroxy-3-methylpentanoic acid
3-o-(alpha-l-arabinopyranosyl)hederagenin Akebia saponin PA: isolated from Dipsacus asperoides; structure in first source. hederagenin 3-O-arabinoside : A triterpenoid saponin that is hederagenin attached to an alpha-L-arabinopyranosyl residue at position 3 via a glycosidic linkage.	3.16	5	alpha-L-arabinopyranoside; hydroxy monocarboxylic acid; monosaccharide derivative; pentacyclic triterpenoid; triterpenoid saponin	plant metabolite
beta-hederin beta-hederin: derived from beta-amyrin; other hederigenin based saponins are available	3.44	7	triterpenoid
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	2.78	3
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
oleic acid Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed). oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry.	7.41	1	octadec-9-enoic acid	antioxidant; Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; Escherichia coli metabolite; mouse metabolite; plant metabolite; solvent
gamma-sitosterol clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.	2.46	2	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; phytosterols	marine metabolite; plant metabolite
euscaphic acid euscaphic acid: isolated from medicinal plant, Euscaphis japonica Pax.; structure; RN given refers to 2alpha,3alpha-isomer. euscaphic acid : A pentacyclic triterpenoid that is urs-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 19 respectively (the 2alpha,3alpha-stereoisomer). It has been isolated from the leaves of Rosa laevigata.	2.07	1	hydroxy monocarboxylic acid; pentacyclic triterpenoid; triol	plant metabolite
boswellic acid [no description available]	2.21	1
glycosides [no description available]	3.78	10
sesquiterpenes [no description available]	2	1
curcumin Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.	2.15	1	aromatic ether; beta-diketone; diarylheptanoid; enone; polyphenol	anti-inflammatory agent; antifungal agent; antineoplastic agent; biological pigment; contraceptive drug; dye; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; EC 1.1.1.21 (aldehyde reductase) inhibitor; EC 1.1.1.25 (shikimate dehydrogenase) inhibitor; EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor; EC 1.8.1.9 (thioredoxin reductase) inhibitor; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; flavouring agent; food colouring; geroprotector; hepatoprotective agent; immunomodulator; iron chelator; ligand; lipoxygenase inhibitor; metabolite; neuroprotective agent; nutraceutical; radical scavenger
chlorogenic acid caffeoylquinic acid: Antiviral Agent; structure in first source. chlorogenate : A monocarboxylic acid anion that is the conjugate base of chlorogenic acid; major species at pH 7.3.	2.03	1	cinnamate ester; tannin	food component; plant metabolite
kaurenoic acid kaurenoic acid: isolated from leaves of Montanoa tomentosa; structure given in first source. ent-kaur-16-en-19-oic acid : An ent-kaurane diterpenoid that is ent-kauran-19-oic acid in which a double bond is present at position 16(17); exhibits anticancer and anti-HIV 1 activity.	2.05	1
cytellin cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982	2.73	3
l 663536 MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.	2.6	1	aryl sulfide; indoles; monocarboxylic acid; monochlorobenzenes	antineoplastic agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; leukotriene antagonist
sc 560 SC560 : A member of the class of pyrazoles that is 1H-pyrazole which is substituted at positions 1, 3 and 5 by 4-methoxyphenyl, trifluoromethyl and 4-chlorophenyl groups, respectively. Unlike many members of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors, SC-560 is selective for COX-1.	2.21	1	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug
quercetin [no description available]	2.85	3	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
acacetin 5,7-dihydroxy-4'-methoxyflavone : A monomethoxyflavone that is the 4'-methyl ether derivative of apigenin.	2.11	1	dihydroxyflavone; monomethoxyflavone	anticonvulsant; plant metabolite
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.59	2	trihydroxyflavone	antineoplastic agent; metabolite
stigmasterol stigmasta-5,22-dien-3-ol: isolated from freeze-dried powder of Blackberries (Rubus ursinus L.) which showed an activity on inhibition of chemocarcinogen. stigmasterol : A 3beta-sterol that consists of 3beta-hydroxystigmastane having double bonds at the 5,6- and 22,23-positions.	2.02	1	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; phytosterols; stigmastane sterol	plant metabolite
kaempferol [no description available]	2.11	1	7-hydroxyflavonol; flavonols; tetrahydroxyflavone	antibacterial agent; geroprotector; human blood serum metabolite; human urinary metabolite; human xenobiotic metabolite; plant metabolite
orientin orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer. orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8.	2.11	1	3'-hydroxyflavonoid; C-glycosyl compound; tetrahydroxyflavone	antioxidant; metabolite
astragalin kaempferol-3-O-glucoside: isolated from the pit of Mahkota dewa; structure in first source. kaempferol 3-O-beta-D-glucoside : A kaempferol O-glucoside in which a glucosyl residue is attached at position 3 of kaempferol via a beta-glycosidic linkage.	2.11	1	beta-D-glucoside; kaempferol O-glucoside; monosaccharide derivative; trihydroxyflavone	plant metabolite; trypanocidal drug
lead Lead: A soft, grayish metal with poisonous salts; atomic number 82, atomic weight 207.2, symbol Pb.	2.03	1	carbon group element atom; elemental lead; metal atom	neurotoxin
beta-escin [no description available]	6.91	51
echinocystic acid echinocystic acid: aglycone moiety of saponin chrysantellin	2.43	2
corosolic acid [no description available]	2.66	2	triterpenoid	metabolite
oleanane oleanane: from the aerial roots of Ficus microcarpa; structure in first source	2.53	2	terpenoid fundamental parent; triterpene
palbinone palbinone: terpenoid isolated from the roots of Paeonia albiflora; structure given in first source; showed strong inhibitory activity against 3-alpha-hydroxysteroid dehydrogenase	2.06	1	16-oxo steroid	metabolite
11-keto-boswellic acid [no description available]	2.21	1
eclalbasaponin i eclalbasaponin I: has antineoplastic activity; isolated from Eclipta prostrata; structure in first source	2.15	1
alpha-synuclein alpha-Synuclein: A synuclein that is a major component of LEWY BODIES and plays a role in SYNUCLEINOPATHIES, neurodegeneration and neuroprotection.	2.15	1
acetyl-11-ketoboswellic acid acetyl-11-ketoboswellic acid: a 5-lipoxygenase inhibitor; structure given in first source	2.21	1	triterpenoid
3-o-acetyl-beta-boswellic acid 3-O-acetyl-beta-boswellic acid: isolated from Boswellia serrata; structure in first source	2.21	1
kalopanax saponin b kalopanax saponin B: isolated from Kalopanax septemlobus; structure given in first source. kalopanaxsaponin B : A triterpenoid saponin with hederagenin as the aglycone part. It has been isolated from the stem bark of Kalopanax pictus.	2.78	3	carboxylic ester; pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; plant metabolite
pulsatilla saponin d [no description available]	2.49	2	triterpenoid	metabolite
ginsenoside ro ginsenoside Ro: from ginseng; RN given refers to ginsenoside Ro, (all-D)-isomer	2.31	1	triterpenoid saponin	metabolite
11-deoxy glycyrrhetinic acid [no description available]	2.21	1	triterpenoid
alpha-amyrenone alpha-amyrenone: from Marsdenia officinalis Tsiang	2.21	1
oleanonic acid oleanonic acid: structure in first source	2.52	2
lyoniside lyoniside: see also eleutherosides & syringin for eleutheroside B: 118-34-3; RN given refers to (3beta)-isomer	2.43	2
2-hydroxyursolic acid 2-hydroxyursolic acid: isolated from the stem bark of Physocarpus intermedius; structure in first source	2.07	1
sapogenins Sapogenins: The aglucon moiety of a saponin molecule. It may be triterpenoid or steroid, usually spirostan, in nature.	3.59	9
arjunic acid arjunic acid: from Terminalia arjuna; structure in first source	2.07	1	triterpenoid
cauloside D [no description available]	2.06	1	carboxylic ester; pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; plant metabolite
23-hydroxybetulinic acid 23-hydroxybetulinic acid: structure in first source	2.06	1	triterpenoid	metabolite
madecassoside [no description available]	2.31	1	carboxylic ester; pentacyclic triterpenoid; trisaccharide derivative; triterpenoid saponin	anti-inflammatory agent; antioxidant; antirheumatic drug; plant metabolite; vulnerary
benzoylpaeoniflorin benzoylpaeoniflorin: from Paeonia lactiflora	2.06	1
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	2.9	2
stigmasterol glucoside stigmasterol glucoside: toxic component of Cycas circinalis seeds possibly etiologic in Guamanian ALS-parkinsonism-dementia complex; structure in first source	2.02	1	steroid
osimertinib osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.	2.21	1	acrylamides; aminopyrimidine; biaryl; indoles; monomethoxybenzene; secondary amino compound; secondary carboxamide; substituted aniline; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
ziyuglycoside i ziyuglycoside I: isolated from the leaves of Hex pupurea; structure in first source	2.31	1
ziyuglycoside ii ziyuglycoside II: isolated from Sanguisorba officinalis; structure in first source	2.31	1
akebia saponin d akebia saponin D: isolated from Dipsacus asper; structure in first source. akebia saponin D : A triterpenoid saponin that is hederagenin attached to a alpha-L-arabinopyranosyl residue at position 3 via a glycosidic linkage and a 6-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl residue at position 28 via an ester linkage. It is the active ingredient found in the traditional Chinese herb Radix Dipsaci.	3.17	5

Condition	Relationship Strength	Studies
Extravascular Hemolysis [description not available]	3.44	7
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	3.44	7
Benign Neoplasms [description not available]	3.03	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.03	1
Leishmania Infection [description not available]	2.15	1
Leishmaniasis A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).	2.15	1
Cancer of Lung [description not available]	3.16	4
Lung Neoplasms Tumors or cancer of the LUNG.	3.16	4
Experimental Neoplasms [description not available]	2.21	1
Carcinoma, Non-Small Cell Lung [description not available]	2.21	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.21	1
Infections, Pneumococcal [description not available]	2.41	1
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	2.41	1
Eczema, Atopic [description not available]	2.41	1
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	2.41	1
Leishmaniasis, American [description not available]	2.41	1
Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes.	2.41	1
Cirrhosis [description not available]	3.22	3
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	3.22	3
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.41	1
Cancer of Cervix [description not available]	2.69	2
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	2.69	2
Acute Kidney Failure [description not available]	2.41	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.13	4
Innate Inflammatory Response [description not available]	4.34	13
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	9.34	13
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	7.41	1
Arthritis, Degenerative [description not available]	2.6	1
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	7.6	1
Blood Poisoning [description not available]	4.21	9
Acute Hepatic Failure [description not available]	4.21	9
Liver Failure, Acute A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.	4.21	9
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	4.21	9
Acute Confusional Senile Dementia [description not available]	2.53	2
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.53	2
Chronic Kidney Diseases [description not available]	2.6	1
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	2.6	1
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	2.6	1
2019 Novel Coronavirus Disease [description not available]	2.6	1
Diabetic Glomerulosclerosis [description not available]	2.6	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.6	1
Infections, Staphylococcal [description not available]	2.21	1
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	2.21	1
Bone Loss, Osteoclastic [description not available]	2.25	1
Alveolitis, Fibrosing [description not available]	2.25	1
Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.	7.25	1
Hepatocellular Carcinoma [description not available]	2.25	1
Cancer of Liver [description not available]	2.25	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.25	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.25	1
Infection, Toxoplasma gondii [description not available]	2.31	1
Toxoplasmosis The acquired form of infection by Toxoplasma gondii in animals and man.	2.31	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.17	1
Cancer of Head [description not available]	2.15	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	2.15	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.48	2
Cancer of Colon [description not available]	2.1	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.1	1
Chronic Illness [description not available]	2.11	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.11	1
Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	7.11	1
Anasarca [description not available]	2.69	3
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2.69	3
Degenerative Diseases, Central Nervous System [description not available]	2.15	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	7.15	1
Liver Dysfunction [description not available]	2.15	1
Liver Diseases Pathological processes of the LIVER.	2.15	1
Asthma, Bronchial [description not available]	2.05	1
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.05	1
Leukemia L 1210 [description not available]	2.02	1
Adjuvant Arthritis [description not available]	1.95	1
Granulomas [description not available]	1.95	1
Granuloma A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.	1.95	1
Acute Liver Injury, Drug-Induced [description not available]	1.98	1
Carbon Tetrachloride Poisoning Poisoning that results from ingestion, injection, inhalation, or skin absorption of CARBON TETRACHLORIDE.	1.98	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	1.98	1
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	2	1

hederagenin

Cross-References

Synonyms (52)

Research Excerpts

Overview

Actions

Treatment

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (6)

Inhibition Measurements

Biological Processes (159)

Molecular Functions (44)

Ceullar Components (40)

Bioassays (124)

Research

Studies (128)

Market Indicators

Research Demand Index: 34.12

Study Types

hederagenin

Cross-References

Synonyms (52)

Research Excerpts

Overview

Actions

Treatment

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (6)

Inhibition Measurements

Biological Processes (159)

Molecular Functions (44)

Ceullar Components (40)

Bioassays (124)

Research

Studies (128)

Market Indicators

Research Demand Index: 34.12

Study Types

Related Drugs (129)

Related Conditions (77)